Let the money flow like the Mississippi River
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Destroyed all cancer cells, cancer free
TransCode believes that TTX-MC138 is the first therapeutic candidate in clinical development designed to specifically target a molecule responsible for metastatic disease across multiple indications and irrespective of the site of metastasis. It has the potential to positively affect patient outcomes in a range of cancers, including breast, pancreatic, ovarian, colon, lung and others. Successful clinical development of TTX-MC138 could represent a breakthrough approach to effectively treating patients with metastatic cancer.
It’s a miracle drug in the rna clinic
They also tested it on rats, and they are also cancer free.. it’s Rna world class the best of the best
Let all hold hand an pray to the mountain top brothers
I have a dream Amgen 5 billion dollar buyout
I have a dream RNAz food and drug administration approval next week fast track status
It’s so exciting getting screwed by the CEO rat bastard white, he screwed investors all his career, hell is where he belongs
They are going to burn it to the ground with another 5 reversals in hell, dirty rat bastards in management screwed investors all their careers, Hell is where CEO Fitzgerald the rat bastard belongs
These dirty rat bastards screwed investors all their careers , hell is where they all belong, They lost all investors confidence
Go on and reverse another 4 times dirty rat bastard CEO screwed investors all his career, burn in hell rat bastard Fitzgerald
Collapse this piece of shit company to the ground you rat bastards
Take all of management and throw them in the garbage in hell where they belong for screwing investors all their careers
Take it to the stinky pinkies and burn it underground in hell where it belongs
Partnership with garbage, This piece of garbage screwed all investors, burn it or the ground you dirty rat bastards
Let them all burn in hell where they belong dirty rat bastards, they screwed all investors all their careers
Still @.23 rat bastards collapse this piece of trash to the ground in hell
Dirty rat scumbag CEO Fitzgerald must burn in hell nailed to the cross. The rat bastard screwed investors all his career
Take it to the tripp’s and to the stinky pinkies, management screwed shareholders all their careers burn in hell rat bastards
Go on rat bastards collapse this piece of shit to the ground, Is that all you got you dirty rat bastards the earth
These scumbags rats bastards of the earth screwed all investors all their careers, burn in hell scumbags
Burn, burn it to the ground, This is backed by dirty scumbags scams of the earth, Hell is where they all belong
CEO burned it to the ground in hell where he belongs nailed to the cross
Burn it to the ground in hell where they belong
Go on scammers, collapse this piece of garbage to the ground and burn in hell
It always happens when your a scam company screwing investors all their careers, Management belong in hell
These scammers can all burn in hell
No body believes in this scam company
Good morning y’all bagholders!!
Good morning bagholders, How does everyone feel living on the streets??
This pharma company moves backwards with progress should be in the tripps by fda approval
we should be at .01 by then brother
That is correct with Greenlane brother!! Going to live the dream with RNAZ FDA fast track rocket 10$
In April 2024, we submitted a Fast-Track SBIR to the NCI in support of clinical development of TTX-siPDL1. If awarded, the SBIR award is expected to provide up to $2.3 million of non-dilutive funding over two years beginning in the second half of 2024. ..."
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced initiation of its Phase 1 multicenter, open-label, clinical study of its lead therapeutic candidate, TTX-MC138.
Two clinical trial sites have been activated with patient enrollment expected to begin during the current quarter. TransCode may activate a total of up to five clinical trial sites, all of which are expected to be activated this quarter.
The Phase 1 clinical trial is designed to generate critical data to support evaluation of the safety of TTX-MC138 in patients with a variety of metastatic solid cancer. It may provide early evidence of TTX-MC138 clinical activity. The trial comprises an initial dose-escalation phase followed by a dose-expansion phase. The primary objective of the dose-escalation phase is to evaluate the safety and tolerability of escalating dose levels of TTX-MC138. In the dose-expansion phase, the safety, tolerability and anti-tumor activity of TTX-MC138 will be further evaluated in certain tumor types selected based on preliminary results from the dose-escalation phase.
“We are thrilled to have garnered such high interest in TTX-MC138 from eminent oncologists working in some of the most respected clinical trial sites in the country,” commented Sue Duggan, Senior Vice President, Operations, at TransCode. “Advancing breakthrough RNA therapeutics science in the clinic is our primary goal as a biotechnology company at the cusp of innovative technology,” added Duggan.
Active and recruiting sites can be found at:
https://clinicaltrials.gov/study/NCT06260774?spons=transcode&rank=1
About TransCode Therapeutics
TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
I’m ready to live the dream
Form 10-Q today RE SBIR Award:
"...In January 2024, we submitted a Direct-to-Phase II SBIR application to the National Cancer Institute, or NCI, in support of clinical development of TTX-MC138. If awarded, the Direct-to-Phase II SBIR award is expected to provide up to $2 million of non-dilutive funding over two years beginning in the second half of 2024.
In April 2024, we submitted a Fast-Track SBIR to the NCI in support of clinical development of TTX-siPDL1. If awarded, the SBIR award is expected to provide up to $2.3 million of non-dilutive funding over two years beginning in the second half of 2024. ..."
Good riddance see you in heaven brother